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Na+ transportsThe Na+ pump and its Endogenous modulator Ouabain (EO) can be considered as an ancestral enzymatic
system, conserved among species ranging from Drosophila to humans, related to Na handling. In this review,
we examine howEO is linkedwith vascular function in hypertension and if it impacts the pathogenesis of heart
and renal failure. Moreover, the molecular mechanism of endogenous ouabain-linked hypertension involves
the sodium pump/sodium–calcium exchanger duet. Biosynthesis of EO occurs in adrenal glands and is under
the control of angiotensin II, ACTH and epinephrine. Elevated concentrations of EO and in the sub-nanomolar
concentration range were found to stimulate proliferation and differentiation of cardiac and smooth muscle
cells. They may have a primary role in the development of cardiac dysfunction and failure. Experimental data
suggest that the Na/K-ATPase α2-catalytic subunit causes EO-induced vasoconstriction. Finally, maneuvers
that promote Na depletion, as diuretic therapy or reduced Na intake, raise the EO levels. Taken together, these
ﬁndings suggest a key role for EO in body Na homeostasis.; fax: +39 0226432384.
.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
For several million years the evolutionary ancestors of humans ate
a diet that contained 1 g salt/day [1]. This implies that present-day
humans are genetically programmed to a salt intake of that amount.
The deliberate addition of salt to food only began ∼5000–10,000 years
agowith the beginning of agriculture so that the present consumption
of ∼10 g/day on average is, in evolutionary terms, relatively recent.
Hypertension is the major risk factor for cardiovascular disease. High
dietary salt is implicated in hypertension; however, the sensitivity of
blood pressure to salt among individuals is variable, and the
mechanisms of salt-sensitive hypertension are speculative [2]. Others
have presumed a causal interrelationship between salt intake, total
body Na+, ﬂuid balance and blood pressure [3]. According to this
model, kidney controls total body Na+ and thereby extracellular
volume homeostasis. Reduced renal Na+ excretion results in
extracellular volume expansion and augmented blood ﬂow. Tradi-
tionally, the Na+ cation is thought to be largely restricted to the
extracellular compartment, while K+ is stored intracellularly. This
balance is maintained by the activity of the Na/K-ATPase in the cell
membrane. The Na/K-ATPase contains a binding site for cardiacglycosides, such as ouabain, digoxin, and digitoxin, that is highly
conserved among species ranging from Drosophila to humans.
Although advantage has been taken of this site to treat congestive
heart failure with drugs such as digoxin, this site has only recently
been shown to have a natural function in blood pressure control [4].
The Na/K-ATPase can be considered as an ancestral enzymatic system
related to Na+ handling that has adapted its function during
evolution. In this review, we examine how sodium and endogenous
ouabain inﬂuence blood pressure and some related disorders. We
examine the evidence for EO biosynthesis in humans, the role of EO in
primary hypertension and in renal Na handling, and in Ménière's
Syndrome. Finally, the trophic effect of EO on cardiovascular function
will be mentioned.2. Biosynthesis and clearance of endogenous ouabain (EO)
Since the original report published in 1991, EO has been isolated
and detected by a variety of independent laboratories on different
continents. HPLC and immunoassay methods show that EO is present
in bovine [5] and human adrenal glands [6], bovine hypothalamus
[7,8], rat adrenomedullary cells [9] and biological ﬂuids [10–13]. Mass
spectrometry, NMR studies and the cochromatography of EO with
ouabain in all tested chromatography systems conﬁrm the presence of
EO beyond doubt and show that the mammalian compound is
identical to plant ouabain [7–9,14–17].
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main source of EO in humans and rats:
1. The adrenal is enriched in EO in many mammals, and the tissue
content remains remarkably constant under different conditions.
Moreover, EO has been isolated and identiﬁed from bovine
adrenals and hypothalamus [7,16].
2. Plasma EO levels declined in adrenalectomized rats but not in rats
whose adrenal medulla was removed [18]. Crucially, with
prolonged adrenalectomy and corticosterone replacement in rats,
plasma EO levels fell to the threshold sensitivity of the radioim-
munoassay used in the study. Thus, the adrenal cortex is required
tomaintain normal plasma EO levels, and extra-adrenal sources are
not sufﬁcient in this capacity.
3. In primary aldosteronism EO levels in the mixed inferior vena cava
blood were more than 5–10 fold higher than in normal controls. If
one assumes that the mixed venous plasma level of EO in adrenal
patients lays between 2 and 4 nmol/L [19], then an approximately
three-fold step up was present in adrenal venous plasma.
4. In another study on conscious afebrile dogs in which adrenal
venous catheters were surgically placed, the EO content of the
adrenal venous efﬂuent was approximately 5–6 fold higher than
that of arterial blood [20].
5. Elevated plasma levels of EO were found in hypertensive patients
with adrenocortical tumors [21]. Removal of the tumors was
associated with a normalization of plasma EO levels and the
remission of hypertension. The results were compatible with those
in other patients with adrenocortical tumors [22] and may
represent the ﬁrst example of ouabain-secreting adrenocortical
tumors causing hypertension.
6. Cultured human and bovine adrenocortical cells secrete EO into the
culture ﬂuid [23]. The secretion is augmented by angiotensin II,
ACTH and possibly by vasopressin as well as alpha-1 adrenoceptor
agonists [22]. ACTH appears to be a key regulator of circulating EO
in humans [24].
The molecular basis for the elevated plasma EO in Milan Hyperten-
sive Strains [10,25] was probed in the hypothalamus and adrenal using
bioinformatics and genomic techniques. Elevated transcripts for
cholesterol side-chain cleavage (also known as cytochrome P450scc,
CYP11A1) and β-hydroxysteroid dehydrogenase/δ5-4 isomerase genes
(HSD3B) were detected in hypothalamus [26]. Other studies have
suggested that, as with aldosterone (Aldo), the biosynthesis of cardiac
glycosides by the adrenal gland likely involves cholesterol side-chain
cleavage to form pregnenolone with further metabolism of progester-
one [27–29]. Recently, we observed marked increases in circulating EO
in uremic patients [30]. These data imply that, in addition to secretion,
renal clearance is one of the major determinants of plasma EO. The
biosynthesis of EO involves cholesterol side-chain cleavage (CYP11A1)
and 3β-hydroxysteroid dehydrogenase (HSD3B) with sequential
metabolism of pregnenolone and progesterone. Furthermore, the
renal excretion of cardiac glycosides is mediated, in part by the organic
anion transporter (SLCO4C1) [31] at the basolateral membrane and in
part by the P-glycoprotein (PGP, encoded by MDR1) [32] at the apical
membrane of the nephron. A single-nucleotide polymorphisms (SNPs)
and haplotype-based association studywas performedwith a total of 26
informative SNPs in a large cohort of hypertensive patients. Among
patients with essential hypertension, CYP11A1 and MDR1 loci were
found associated to circulating EO and Diastolic Blood Pressure (DBP),
most likely by inﬂuencing EO synthesis and transmembrane transport,
respectively [33].
3. Endogenous ouabain in hypertension and renal Na handling
Human kidneys are poised to conserve sodium and excrete
potassium. Prehistoric humans, who consumed a sodium-poor and
potassium-rich diet, were well served by this mechanism [34]. Withsuch a diet, sodium excretion is negligible and potassium excretion is
high, matching potassium intake. In the contemporary dietary
environment where high intakes of salt are common, the kidney
must meet the obligation to excrete excess salt. Accordingly, it is of
considerable interest that the reabsorption of ﬁltered sodium by the
renal tubules is increased in primary hypertension [35]. The
augmented reabsorption appears to be mediated by the stimulation
of several sodium transporters located at the luminal membrane, as
well as the sodium pump, which is localized to the basolateral
membrane and provides the energy for such transport. The circulating
levels of EO change in response to variation of Na balance.
In studies on the relationship between Na intake/Na excretion and
EO in various human experimental conditions, we noted the following:
a) In a study of the general population [36], EO behaved as a blood
pressure modulating factor whose circulating levels were linked
with variations in plasma potassium. We suggested that EO acted
either by inhibiting the pressor effect of an excessive salt intake or
by counteracting the depressor action of sodium depletion.
Furthermore, in 190 subjects whose plasma ouabain was equal
to or less than 140 pmol/l (median), each 50 mmol/day increment
in urinary sodium excretion was associated with an increase in
blood pressure averaging 2.2 mm Hg (95% CI, 0.7–3.6 mm Hg;
P=0.004) systolic and 1.4 mm Hg (95% CI, 0.3–2.5 mm Hg;
P=0.01) diastolic [36]. In contrast, in subjects whose plasma
ouabain was higher than 140 pmol/l, the association between
blood pressure and urinary sodium excretion was not statistically
signiﬁcant. One possible interpretation of our ﬁndings is that EO
might play a central role in the homeostatic regulation of blood
pressure in response to changes in sodium intake in normotensive
subjects [36].
b) The impact of long-term alterations in sodium balance on the
circulating levels and renal clearance of EO in normal humans have
been investigated [37]. Thirteen normal men consumed a normal
diet, high-salt diet, and hydrochlorothiazide (HCTZ), each for 5-day
periods to alter sodium balance. In 13 normotensive subjects
response to the high-salt diet, plasma EO increased N13-fold
reaching 5.8±2.2 nmol/L (Pb0.05) on the 3rd day of the diet.
DuringHCTZ, bodyweightdecreased andPRA,ALDO, andEO (1.71±
0.77 nmol/L) rose, while urinary EO excretion remained within the
normal range (1.44±0.31 nmol/day). The net result of the above-
mentioned study is that high-salt diet and HCTZ raise plasma EO by
stimulating EO secretion, and a J-shaped curve relates sodium
balance with EO in healthy men (Fig. 1).
c) In never-treated, newly discovered patients with essential
hypertension, there is a bimodal distribution of plasma EO levels
[38]. The lower mode was 207±74 pmol/l (not different from
that of normotensive controls, 253±53 pmol/l). The highermode,
representing approximately 40–45% of the patients with essential
hypertension, was 540±197 pmol/l. Compared with patients
with low EO, those with high EO essential hypertension had lower
heart rates but increased stroke index and ventricular mass as
expected with an entity having functional cardiotonic steroid
activity.
d) In hypertensive patients and in contrast to long-held hypotheses,
acute salt loading was not an immediate stimulus to plasma EO.
Basal levels of plasma EO do not differ among patients with salt-
sensitive or salt-resistant hypertension [39]. We studied 138
patients with essential hypertension who underwent an acute
volume expansion/contractionmaneuver (2 days) and 20 patients
who entered a blind randomized crossover design involving
chronically controlled sodium intake and depletion (170 to
70 mmol/day; 2 weeks each period). In both maneuvers, plasma
levels of EO were higher during Na depletion (acute: 338.8±17.4
and 402.7±22.8 pmol/l for baseline and low sodium, respectively,
P=0.01; chronic: 320.4±32.0 versus 481.0±48.1 pmol/l,
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(Fig. 1). Taken together, these evidences suggest that EO is
involved in the adaptation of humans to sodium depletion and
this argues against the hypothesis that EO is a natriuretic hormone
at least under these conditions.
e) Among patients with more advanced hypertension, circulating
levels of EO were directly related to both BP and total peripheral
resistance and inversely related to cardiac index [40].
f) We reported that circulating EO in hypertensive patients is raised
speciﬁcally by maneuvers that promote the loss of body sodium
[14,41]. Acute expansion of body ﬂuids with isotonic saline is not a
stimulus to plasma EO. Moreover, in hypertensive patients [41]
carrying the mutated alpha-adducin (ADD1) variant, there is
increased Na reabsorption with consistent suppression of PRA,
Aldo and EO. Finally, patients with high plasma EO levels ormutated
alpha-adducin display an increased BP and proximal tubular
reabsorption [40]. A positive correlation (r2=0.9, Pb0.001) was
observed between plasma EO measured by both LC–MS/MS and
radioimmunoassay in 21 patients. The plasmaNa concentrationwas
positively correlated with baseline plasma EO. Increased tubular
reabsorption of Na+ has been proposed as an independent
determinant of hypertension [42]. Our ﬁndings suggest a possible
involvement of EO in this mechanism. The overall tubular reabsorp-
tion, expressed as FENa (Fractional Excretion of Na), and proximal
tubular reabsorption, expressed as FELi (Fractional Excretion of Li),
decreased in hypertensives with high EO levels.
All together these ﬁndings suggest that EO has a double effect at
renal level: normal circulating values (less than 250 pM) by
stimulating the basolateral Na/K-ATP, induce a signaling cascade
that lead to an increase of Na+ reabsorption, through the renal Na/
Ca exchanger (NCX1). On the other hand, elevated plasma EO induce
natriuresis. Indeed, recently we showed that hypertensive patients
with elevated plasma EO (N323 pmol/l) showed increased FENa and
increased Na tubular rejection fraction (P=0.007) after acute saline
load [Manunta P. unpublised data]. Furthermore, the effect of renin
angiotensin aldosterone system (RAAS) and EO have been investi-
gated: RAAS reﬂects body sodium status and has primarily a com-
pensatory role in the regulation of BP. Conversely, EO has a biphasic
relationship with tubular reabsorption (favoring Na retention at low
plasma levels and Na excretion at the higher levels) which is likely
to affect total body Na and blood pressure. The rise in circulating EOFig. 1. The relationship between sodium balance and circulating EO is described by a
J-shaped curve: acute and chronic diuretic treatment, furosemide and HCTZ, (Negative
Na balance), raise EO; at steady state of body Na balance (Normal) the circulating EO
returns to basal values; during high-salt diet or acute volume expansion (Positive) the
natriuretic effect is present in those with increased EO.is due either to the genetic or renal clearance background. It has
been shown that among patients with essential hypertension,
CYP11A1 and MDR1 loci are related to circulating EO and DBP,
most likely by inﬂuencing EO synthesis and transmembrane
transport, respectively [33].
4. Endogenous ouabain in a Na related disease
Ménière's disease (MD) is an inner ear disorder characterized by
recurrent rotational vertigo and ﬂuctuating sensorineural hearing loss.
The pathogenetic mechanism is commonly accepted to be a raised
endolymphatic pressure (hydrops). The peculiar ionic composition of
endolymph, high K+ and low Na+ concentrations [43], is essential to
mechano-electric transduction by hairy cells [44]. Na/K-ATPase has
been abundantly demonstrated in the inner ear [45,46]. High concen-
trations of ouabain inhibit Na/K-ATPase activity in guinea pig inner ear
[47]. Perilymphatic perfusion of ouabain decreases the endocochlear
potential and induces ultrastructural changes in the stria vascularis [48].
Moreover, round window application of ouabain has been found to
produce degeneration of outer hair cells and spiral limbus ﬁbrocytes in
the cochlea in guinea pigs [49].
The plasma levels of EO in MD patients [50,51]according to ADD1
Gly460Trp polymorphism were not different compared to controls
even if their genotypic frequencies differed signiﬁcantly (P=0.0013,
chi-square=5.29). As Ménière disease has a complex pathology, we
suppose that ADD1 and plasma EO may act as independent factors in
inner ear on the pump activity modulation. The small group of
patients studied is not enough to detect the differences seen in larger
group of hypertensives. This example of dysregulation of tissue
sodium balance is in agreement with the observations done in
hypertensive patients, where the ADD1 locus and plasma EO interact
and are related with whole body sodium status.
5. Endogenous ouabain and cardiovascular structure and function
EO activates signal transduction via the Src–epidermal growth
factor receptor (EGFr)–extracellular signal-regulated kinase (ERK)
pathway, and thereby triggers growth and proliferation of renal
tubular cells and cardiomyocytes in vitro and in vivo, even at sub-
nanomolar concentrations [52]. We therefore investigated the
association between left ventricular structure and function and
plasma EO in different conditions:
I. In young offspring of hypertensive individuals, plasma EO
levels positively correlate with some indices of diastolic cardiac
dysfunction that precede the development of hypertension and
left ventricular hypertrophy (LVH) [53].
II. Left ventricular structure and function and plasma EO have
been studied in a general population [54]. We randomly
recruited 536 individuals from a general population (50.7%
women, mean age 53.1 years). Measurements included echo-
cardiographic left ventricular structure and function, blood
pressure, plasma EO, and the 24-h urinary excretion of sodium.
The key ﬁnding was that systolic blood pressure and left
ventricular wall thickness increased with plasma EO. The
signiﬁcant positive association of relative wall thickness with
plasma EO reﬂected increased left ventricular wall thickness
and a slightly decreased left ventricular internal end-diastolic
diameter. Our population-based study suggested that EO may
have a trophic effect on the myocardium, independently from
BP and other covariables. Elevated EO might be a factor that
contributes to an increased risk of LV remodeling and
hypertrophy amongst patients with essential hypertension.
III. Among patients with idiopathic dilated cardiomyopathy, high
circulating levels of EO (N233 pmol/l) identify those indivi-
duals predisposed to progress more rapidly to heart failure
1217P. Manunta et al. / Biochimica et Biophysica Acta 1802 (2010) 1214–1218[55]. Moreover, patients on digoxin therapy display higher
levels of EO (396.4±187 pmol/l) than patients without
therapy (211.6±71 pmol/l), and this difference persists
when all confounders (including the potential cross-reactivity
with digoxin) are taken into account [25]. The results also
imply that digoxin should not be given to patients with high EO
perhaps because of the potential for overt toxicity.
IV. In patients with severe cardiomyopathy and end-stage renal
disease (ESRD) in dialysis [19], plasma EO was independently
associated with left ventricular mass and geometry. This
association was independent of arterial pressure and other
well-established determinants of left ventricular mass. In ESRD,
left ventricular hypertrophy and high cardiovascular risk in
general represent multifactorial problems. Blood pressure,
anaemia [56], hypoalbuminaemia, dyslipidaemia, hyperpara-
thyroidism [57] and high sympathetic activity [58] all contrib-
ute to increased cardiovascular risk and LVH in these patients.
Our study, once again, conﬁrms that systolic BP, haemoglobin
and cholesterol impact upon LVH in ESRD. In addition, our
novel ﬁnding that EO was associated with LVH and that it is a
marker of essential hypertension is fully in keeping with the
notion that chronic volume overload is a potent stimulus that
upregulates the steady-state levels of EO. A reduced capacity of
the ventricular wall to develop hyperthrophy [59] and
cardiomyocyte apoptosis triggered by ouabain [60] remain as
hypothetical possibilities for the explanation of the eccentric
LVH–EO link in ESRD. We also evaluated some of our radioim-
munoassaydeterminationswith liquid chromatography–tandem
mass spectrometry (LC–MS/MS) in these patients. The EO
content of the samples by LC–MS/MS and radioimmunoassay
were highly correlated (r2=0.94) in linear regression analysis.6. Conclusion
The results summarized here emphasize the role of EO in nor-
motensive and hypertensive subjects. First, the hypertensinogenic
effects of EO are in keeping with the experimental evidence indicating
that the α2-catalytic subunit causes hypertension and ACTH-induced
high BP [61,62]. Furthermore, the mutation of the α2-Na+ pump
ouabain-binding site abolishes the hypertensinogenic effect of
ouabain and ACTH [63]. Recently, it has been shown that the dynamic
myogenic constriction in response to circulating nanomolar ouabain
in small arteries likely makes a major contribution to the increased
vascular tone and rise blood pressure in ouabain hypertensive rats
[64]. Accordingly, this vascular mechanismmay be relevant in human
primary hypertension where elevated plasma EO levels are correlated
with blood pressure in 40–50% of patients [38–41].
Second, in addition to its direct inﬂuence on ion transport and
vascular tone, ouabain is a growth factor that activates signaling
cascades via a Src kinase pathway linked to the Na,K-ATPase [65,66].
The EO effect on structural and hyperthrophic cardiac myocytes has
been discussed [40,52–55]. Third, the data presented demonstrate a
concentration-dependent relationship of EO with Na metabolism: its
effect on tubular reabsorption which is likely to directly affect total
body Na and blood pressure [39]. Recently, data in knock-out mice
[62,63] suggest that the ouabain-binding site of the Na/K-ATPase
affects the natriuretic response to a salt load by responding to
endogenous Na,K-ATPase ligands. However, maneuvers that promote
Na depletion [37,39] (reduced Na intake, diuretic therapy) raise
plasma EO (J curve, Fig. 1).
The experimental evidences are in keeping with our initial
hypothesis that EO and the Na pump are ancestral systems related to
Na handling and that their interaction evolved and was physiologically
relevant under conditions where salt intake was low. The association of
EOwith essential hypertension and cardiac hypertrophy are likely to berecent phenomena that reﬂect the widespread introduction of salt into
cooking and food preservation in the last few millennia.
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